Maxwell Skor
Stock Analyst at Morgan Stanley
(2.63)
# 2,592
Out of 5,014 analysts
6
Total ratings
80%
Success rate
12.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $164.40 | -12.41% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $214.77 | +16.40% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $4.45 | +169.66% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $2.17 | +360.83% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $1.89 | +87.83% | 2 | Nov 20, 2024 |
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $164.40
Upside: -12.41%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $214.77
Upside: +16.40%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $4.45
Upside: +169.66%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $2.17
Upside: +360.83%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $1.89
Upside: +87.83%